Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound for preventing and treating metabolic diseases and application thereof

A technology for metabolic diseases, compounds, applied in the field of pharmacy

Inactive Publication Date: 2011-11-09
SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI
View PDF7 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Currently known cell endogenous SREBP inhibitors such as 24-hydroxycholesterol, 25-hydroxycholesterol (25-HC) and 27-hydroxycholesterol, which are also LXR agonists, these small molecules cannot act as anti-hyperlipidemia-related diseases. potential drug composition

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound for preventing and treating metabolic diseases and application thereof
  • Compound for preventing and treating metabolic diseases and application thereof
  • Compound for preventing and treating metabolic diseases and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0232] 10) The preparation method of the CsCl gradient is as follows: add 2.0ml of CsCl solution with a density of 1.40g / ml (the same solvent as above), then add 3.0ml of a CsCl solution with a density of 1.30g / ml, and then add 5ml of virus suspension. Centrifuge at 20,000 rpm for 2 hours at room temperature.

[0233] 11) Collect the virus bands with a density between 1.30g / ml and 1.40g / ml into the dialysis bag (use 10mM EDTA-Na 2 boil for 10 minutes). In dialysis buffer (50g sucrose, 10ml 1M Tris-HCl, pH8.0, 2ml 1M MgCl 2 Dilute to 1 L), dialyze at 4°C for 24 hours, and change the dialysate once in the middle. The virus was collected, and the virus titer was determined (see the manual of the Stratagene Virus Titer Quantification Kit for the specific determination method).

[0234] Adenovirus-mediated SCAP gene silencing in mouse liver

[0235] The inventor adopts AdEasy TM The adenoviral expression vector (purchased from Stratagene) system mediated mouse liver SCAP gene ...

Embodiment 1

[0247] Example 1, Betulin is a specific inhibitor of the SREBP pathway

[0248] The active form of SERBP in the nucleus promotes the expression of downstream genes by combining with the sterol regulatory element (SRE) in the promoter region of the target gene, thereby promoting the biosynthesis of lipids (Wang, X. et al. (1993). Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. II. Purification and characterization. J. Biol. Chem. 268, 14497-14504). The present inventors have constructed a luciferase reporter gene system, the promoter region of the luciferase contains a sterol regulatory element (SRE), and the luciferase is stably expressed in the human liver cancer cell line Huh-7 cells, and finally Huh -7 / SRE-Luc cells ( figure 1 A) Use as a screen for small molecule inhibitors of the SREBP pathway. After the cells are treated with different candidate compounds for a certain period of time, the cells are collected and the ch...

Embodiment 2

[0252] Example 2, Betulin down-regulates the expression of SERBP target genes and reduces cellular lipid synthesis

[0253] Since SREBP-2 is its own target gene (Sato, R. et al. (1996).Sterol-dependent transcriptional regulation of sterol regulatory element-binding protein-2.J.Biol.Chem.271,26461-26464), so SERBP -2 expression was downregulated by approximately 40% after betulin treatment. At the same time, the inventors detected the expression of other dozens of SREBP-2 target genes involved in the cholesterol synthesis pathway such as HMGCR, HMG-CoA synthetase (HMGCS), and Squalene Epoxidase (SE) after betulin treatment were significantly down-regulated ( Figure 4 A). At the same time, the expression levels of genes and enzymes involved in the cellular fatty acid synthesis pathway, such as SREBP-1c, fatty acid synthase (FAS), and acetyl-CoA carboxylase α (ACC), were significantly down-regulated by betulin ( Figure 4 B). Furthermore, consistent with previous observation...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Densityaaaaaaaaaa
Densityaaaaaaaaaa
Login to View More

Abstract

The invention relates to a compound for preventing and treating metabolic diseases such as hyperlipemia, atherosclerosis, II type diabetes, and the like as well as application thereof. The invention discloses an inhibitor of a new SREBP (Sterol Regulatory Element Binding Protein) path. The inhibitor can be used for specifically inhibiting the lipophilic synthesis of cholesterin, fatty acid and triglyceride and reducing the lipid level, thereby providing a new path for preventing and treating the metabolic diseases such as adiposity, atherosclerosis, II type diabetes, and the like.

Description

technical field [0001] The invention belongs to the field of pharmacy; more specifically, the invention relates to a compound for preventing and treating metabolic diseases such as hyperlipidemia, atherosclerosis and type II diabetes and its application. Background technique [0002] Metabolic diseases such as atherosclerosis and type II diabetes have become more and more serious worldwide health problems. It is known that their occurrence is closely related to hyperlipidemia. For example, high cholesterol levels in the blood cause hypercholesterolemia, which in turn induces atherosclerosis, which is the most common cause of cardiovascular diseases such as coronary heart disease, stroke, and myocardial infarction; blood fatty acids and triglycerides High ester levels will cause hypertriglyceridemia, which is the main cause of insulin resistance and type 2 diabetes. Due to the pathogenicity of hyperlipidemia, lipid-lowering is an important component in the treatment and prev...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/56A61P3/00A61P3/10A61P3/06A61P1/16A61P5/50A61P3/04A61P9/10
CPCA61K31/56A61P1/16A61P3/00A61P3/04A61P3/06A61P3/10A61P5/50A61P9/00A61P9/10Y02A50/30
Inventor 宋保亮唐静洁李家贵李培山戚炜
Owner SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com